{'fraction_non_alphanumeric': 0.028764805414551606, 'fraction_numerical': 0.030456852791878174, 'mean_word_length': 6.132530120481928, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical outcome in children with recurrent neuroblastoma treated with ABT‐751 and effect of ABT‐751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro

ABT‐751, an orally bioavailable sulfonamide, binds β‐tubulin to inhibit microtubule polymerization. We described response and event‐free survival (EFS) in children with neuroblastoma and other solid tumors receiving ABT‐751, assessed in vitro cytotoxicity of ABT‐751 and evaluated the effect of ABT‐751 on tubulin polymerization in peripheral blood mononuclear cells (PBMC) and pediatric tumor cell lines.